Internal link ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy Juli 21, 2020 at 11:00 AM UTC
Internal link ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures Juli 14, 2020 at 08:30 PM UTC
Internal link ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen Juli 13, 2020 at 08:30 PM UTC
Internal link ProQR Announces Expert Perspectives Conference Call Series Juni 12, 2020 at 11:00 AM UTC
Internal link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO) Juni 08, 2020 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2020 Operating and Financial Results Mai 07, 2020 at 11:00 AM UTC
Internal link ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update März 31, 2020 at 10:00 AM UTC
Internal link ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome März 25, 2020 at 08:15 PM UTC
Internal link ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update Februar 26, 2020 at 12:00 PM UTC
Internal link ProQR to Present at Cowen and Company 40th Annual Health Care Conference Februar 24, 2020 at 12:00 PM UTC
Internal link ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases Februar 06, 2020 at 12:00 PM UTC
Internal link ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a Januar 30, 2020 at 12:00 PM UTC